Welcome to our dedicated page for Vera Therapeutics SEC filings (Ticker: VERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell 1,800 common shares of VERA.
The filing lists the shares as restricted stock vesting under a registered plan with a vesting/transaction date of 02/20/2026 and a filing/receipt date of 02/23/2026. The securities are listed on NASDAQ.
Morgan Stanley Smith Barney LLC submitted a Rule 144 notice to sell 2,600 shares of common stock of VERA (listed on NASDAQ). The sale is tied to restricted stock vesting under a registered plan with an effective date of 02/20/2026.
VERA submitted a Form 144 notice for a proposed sale of 5,700 shares of common stock tied to restricted stock vesting under a registered plan, dated 02/20/2026. The filing appears on or about 02/23/2026 and references NASDAQ.
Morgan Stanley Smith Barney LLC reported the sale of 2,500 restricted common shares under a registered plan, with the transaction dated 02/20/2026 and the Form 144 filed on 02/23/2026. The filing lists an aggregate amount of $105,087.50 and identifies the exchange as NASDAQ.
Reporting notification to sell 2,900 common shares. The Form 144 filing lists 2,900 shares of common stock proposed for sale through Morgan Stanley Smith Barney LLC with dates 02/20/2026 and 02/23/2026.
The filing describes the shares as restricted stock vesting under a registered plan and identifies the transaction as an issuer‑related sale; cash‑flow treatment and sale timing are not detailed in the excerpt.
VERA submitted a Rule 144 notice to sell 16,600 common shares. The filing lists Morgan Stanley Smith Barney LLC as broker and describes the shares as restricted stock vesting under a registered plan, with a transaction date of 02/20/2026 and a filing date shown as 02/23/2026.
T. Rowe Price Associates, Inc. reports beneficial ownership of 5,461,988 shares of Vera Therapeutics common stock, representing 7.7% of the class as of December 31, 2025. It has sole voting power over 5,376,319 shares and sole dispositive power over 5,461,976 shares, with no shared voting or dispositive power.
The firm states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Vera Therapeutics. T. Rowe Price Associates also affirms that the filing should not be construed as an admission that it is the beneficial owner of these securities.
Vera Therapeutics SVP of Finance and Chief Accounting Officer Joseph R. Young received new equity awards. On February 4, 2026, he was granted 10,000 shares of Class A Common Stock in the form of restricted stock units at $0 per share, bringing his directly held stock to 67,839 shares.
He was also granted stock options for 20,000 shares of Class A Common Stock at an exercise price of $42.74 per share, all held directly. The RSUs vest in four equal annual installments each February 20 from 2027 through 2030, while the options vest over 48 months starting March 4, 2026, subject to his continued service.
Vera Therapeutics President and CEO Fordyce Marshall reported new equity awards tied to continued service. On February 4, 2026, he received 68,800 RSUs of Class A common stock at no cost under the 2021 Equity Incentive Plan, vesting in four equal annual installments each February 20 from 2027 through 2030.
He was also granted a stock option for 137,500 shares of Class A common stock at an exercise price of $42.74 per share, with 1/48 vesting on March 4, 2026 and the remainder vesting monthly thereafter. Following these awards, Marshall reports 274,088 Class A shares held directly, plus indirect holdings of 122,949 shares through a GRAT and 99,081 shares through The Fordyce Revocable Trust.
Vera Therapeutics’ chief financial officer Sean Grant received new equity awards in the form of restricted stock units and stock options. On February 4, 2026, he was granted 25,000 RSUs tied to Class A Common Stock and a stock option for 50,000 shares at an exercise price of $42.74.
The RSUs vest in four equal annual installments on February 20 of 2027, 2028, 2029 and 2030, subject to continued service. The option vests over four years, beginning March 4, 2026, with monthly vesting thereafter, also conditioned on continued service. Following this grant, Grant directly holds 119,130 Class A shares plus 50,000 options, and 5,000 additional shares are held indirectly through a trust.